Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Eco Wave Power (NASDAQ: WAVE) reported that its onshore wave energy technology was featured for the second time in NVIDIA Founder and CEO Jensen Huang's GTC keynote, this time at GTC Taipei 2026.
The company is also progressing its planned pilot wave energy installation at Suao Port, Taiwan, after its local partner secured a land use agreement.
Wave Life Sciences (Nasdaq: WVE) announced participation in two June 2026 investor conferences.
- Jefferies Global Healthcare Conference: June 3, 2026, fireside chat at 10:30 a.m. ET.
- Goldman Sachs 47th Annual Global Healthcare Conference: June 8, 2026, fireside chat at 8:00 a.m. ET.
Live webcasts and limited-time replays will be available on Wave’s investor relations site under Investor Events.
Wave Life Sciences (NASDAQ:WVE) became an inaugural industry sponsor of AlphaDetect, a nonprofit powered and funded by the Alpha-1 Foundation, on May 19, 2026.
The partnership supports routine, targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) via free genetic testing, provider engagement, and practice-level detection tools, aiming to address substantial underdiagnosis.
Wave Life Sciences (Nasdaq: WVE) reported updated Phase 1b/2a RestorAATion-2 data for WVE-006 in alpha-1 antitrypsin deficiency. Biweekly 200 mg dosing generated wild-type M-AAT at 64.4% of total AAT with 11.9 µM total AAT and reduced harmful Z-AAT by 70.5%, similar to 400 mg monthly (58.7% M-AAT, 13.6 µM total, 67.7% Z-AAT reduction).
Editing was sustained at least three months after last dose, with three observed acute phase responses showing dynamic AAT increases and strong CRP-AAT correlation. According to Wave, WVE-006 remained generally safe and well tolerated, and FDA feedback on a potential accelerated approval path is expected mid-2026.
Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focused on RNA medicines, announced that President and CEO Paul Bolno will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City.
The presentation is scheduled for Wednesday, May 20, 2026 at 8:00 a.m. ET, with a live webcast and replay accessible for a limited time via the Investors section of the company website under Investor Events.
Wave Life Sciences (Nasdaq: WVE) reported Q1 2026 results and a pipeline update. Cash and equivalents were $544.6M as of March 31, 2026, with runway into 3Q 2028. Key clinical milestones include FDA acceptance of the Phase 2a multidose INLIGHT trial for WVE-007 and upcoming AATD data presentations in May 2026.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on April 28, 2026 to review first quarter 2026 financial results and provide business updates.
Investors and analysts can access the live event via the company’s Investor Events page, participate in a live Q&A, and find an archived webcast afterward.
Wave Life Sciences (Nasdaq: WVE) has applied to redomicile its parent company from Singapore to the United States via a Scheme of Arrangement under Section 210 of the Companies Act 1967 (Singapore).
The company filed the application on April 16, 2026. A Singapore High Court hearing is set for April 29, 2026 at 10:00 am SGT. Affidavits and written submissions are due April 22 and April 24, 2026, respectively. The Scheme remains subject to shareholder and court approval, and filing materials will be posted on the company investor relations website.
Wave Life Sciences (Nasdaq: WVE) announced its board approved a plan to redomicile the parent company from Singapore to the United States, creating a new Delaware parent corporation.
The one-for-one share exchange will preserve Nasdaq listing and ticker WVE, is expected to take effect in mid-2026, is subject to shareholder and Singapore High Court approvals, and is expected to be tax-free to U.S. shareholders.
Wave Life Sciences (NASDAQ: WVE) reported positive Phase 1 INLIGHT interim data for WVE-007: a single 240 mg dose produced placebo-adjusted -14.3% visceral fat (p<0.05) and -3.3% waist circumference at six months, with lean mass +2.4% and durable Activin E suppression up to 88%. WVE-007 was generally safe to 600 mg with no serious TEAEs. Phase 2a multidose (BMI 35–50 kg/m2) is on track to start in 2Q 2026 to evaluate heavier individuals and additional cardiometabolic endpoints.